Through transcriptional activation, saRNA therapeutics promise a revolution in our ability to modulate previously undruggable targets.

Through transcriptional activation, saRNA therapeutics promise a revolution in our ability to modulate previously undruggable targets.

DEVELOPMENT PROGRAMS

MTL-CEBPA

The CEBPA gene encodes CCAAT/enhancer binding protein alpha (C/EBP-α), a transcription factor that acts as a master regulator of cell lineage determination and differentiation of myeloid cells and other cells types around the body. Myeloid cells are frequently dysregulated in the microenvironment of solid tumours and are understood to be an important resistance hurdle for many anti-cancer medicines. Restoring CEBPA expression in myeloid cells is hypothesised to alter immune cell populations in the tumour microenvironment and improve the efficacy of cancer therapies in solid tumour malignancies.

MTL-CEBPA DRUG PRODUCT

OUTREACH CLINICAL TRIAL

OUTREACH is a multi-centre Phase Ib clinical study of MTL-CEBPA in combination with Sorafenib in patients with primary liver cancer. The study is assessing the safety, tolerability, pharmacology and anti-tumour activity of MTL-CEBPA in combination with Sorafenib. The study is ongoing in the United Kingdom, Singapore and Taiwan.

To learn more about the OUTREACH clinical trial, please visit ClinicalTrials.gov.

TIMEPOINT CLINICAL TRIAL

TIMEPOINT is a multi-centre Phase I/Ib clinical study of MTL-CEBPA in combination with Pembrolizumab in patients with advanced solid tumours. The study is assessing the safety, tolerability, pharmacology and anti-tumour activity of MTL-CEBPA in combination with Pembrolizumab. The study is ongoing in the United Kingdom.

To learn more about the TIMEPOINT clinical trial, please visit ClinicalTrials.gov.

By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close